Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indacaterol/mometasone - Novartis

Drug Profile

Indacaterol/mometasone - Novartis

Alternative Names: Atectura; Atectura Breezhaler; IND/MF; Mometasone furoate/indacaterol acetate; Mometasone/indacaterol; QMF Twisthaler®; QMF-149

Latest Information Update: 30 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis; Schering-Plough
  • Developer Merck & Co; Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Glucocorticoids; Indans; Pregnadienediols; Quinolones; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 11 May 2023 Phase-III clinical trials in Asthma (In children, Treatment-experienced) in South Africa (Inhalation) (NCT05562466)
  • 01 Oct 2022 Novartis Pharmaceuticals plans a phase III trial for Asthma (Child, Treatment experienced) , NCT05562466)
  • 29 Apr 2022 Novartis announces intention to file regulatory applications for Asthma (In children, In adolescents) in or after 2027 (Novartis pipeline, April 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top